MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.17
+0.74
+3.45%
Closed 16:00 04/02 EDT
OPEN
21.29
PREV CLOSE
21.43
HIGH
22.25
LOW
20.79
VOLUME
267.57K
TURNOVER
--
52 WEEK HIGH
31.54
52 WEEK LOW
15.18
MARKET CAP
1.40B
P/E (TTM)
-5.2116
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TBPH stock price target is 31.57 with a high estimate of 40.00 and a low estimate of 20.00.

EPS

TBPH News

More
  • Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue?
  • Zacks · 03/25 16:30
  • Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94
  • Investor's Business Daily · 03/23 23:32
  • Seth Klarman Sees Bargains as the Market Heads Further Into Chaos
  • GuruFocus.com · 03/21 01:02
  • Pulmonx Files Initial U.S. IPO Registration Statement
  • Seeking Alpha - Article · 03/05 17:48

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About TBPH

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
More

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.